[Table_Chart] 公司价格与恒生指数走势比较 -100% 0% 100% 200% 科伦博泰生物-B 恒生指数 分析师：谭国超 执业证书号：S0010521120002 邮箱：tangc@hazq.com [Table_Author] 分析师：任婉莹 执业证书号： S0010525060003 邮箱：renwanying@hazq.com 科伦博泰生物 [Table_StockNameRptType] -B（6990.HK） 港股点评 半年销售增长迅猛，pharma 之势渐成 | 投资评级：买入（维持） [Table_Rank] | | | | --- | --- | --- | | 报告日期： | 2025-8-24 | | | [Table_BaseData] 收盘价（港元） | | 466.66 | | 近 12 月最高/最低（港元） | | 476.2/152 | | 总股本（百万股） | 33 | 2 | | 流通 H 股（百万股） | | 163 | | 流通股比例（%） | | 69.9% | | 总市值（亿港元） | | 1088.05 | | 流通市值（亿港元） | | 759.4 ...

撰文丨王聪 编辑丨王多鱼 排版丨水成文 芦康沙妥珠单抗 （ Sacituzumab tirumotecan，sac-TMT） 是由 科伦博泰 开发的一款 TROP2 靶向的抗 体药物偶联物 （ TROP2- ADC） ，该 ADC 药物已在国内获批上市，用于治疗晚期三阴性乳腺癌。此 外，该药物还在进行多项临床试验，治疗非小细胞包肺癌等多种癌症。 2025 年 8 月 19 日，中山大学肿瘤防治中心 方文峰 教授、 张力 教授团队 在 Nature Medicine 期刊发表 了题为： First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial 的临床研究论文。 该论文首次发布了 芦康沙妥珠单抗 （ 科伦博泰开发的 TROP2 靶向的 ADC 药物 ） 联合 塔戈利单抗 （ tagitanlimab， 科伦博泰开发的抗 PD-L1 单抗 ） 一线治疗 驱动基因阴性晚期 或转移性 非小细胞肺癌 （ NSCLC） 的 OptiTROP-Lung01 研究的 2 ...

1. Report Industry Investment Rating - Not provided in the given content 2. Core Viewpoints of the Report - The Hong Kong innovative drug sector's valuation has not reached its peak and is below the 50% quantile. The industry is in a high - prosperity stage with improving performance in innovative drugs and CXO [1][11] - The innovative drug industry is entering a recovery phase in 2025, driven by industry trends, policies, and events. BD licensing of Chinese innovative drugs overseas is booming, indicating international recognition [2] - The Hong Kong Innovative Drug ETF (513120.OF) has advantages such as good liquidity, high - purity composition, and convenient trading, making it a good investment tool [4] 3. Summary by Directory 3.1 Value Analysis - **Valuation Level**: The PE of the China Securities Hong Kong Innovative Drug Index on August 8, 2025, was 45.73, below the 50% quantile (47.42x), indicating that the valuation of the Hong Kong innovative drug sector has not reached its peak [9] - **Performance Improvement**: The performance of innovative drugs (Biotech + Pharma) and CXO is improving. After ten batches of centralized procurement, innovative drug varieties of Pharma companies are becoming the main growth force, and leading biotech companies' products are rapidly expanding. CXO's performance is also rebounding due to the high - prosperity of the innovative drug track [11][13] - **Representative Companies**: Companies like BeiGene, Kelun Botai, and others have strong R & D capabilities, rich pipelines, and successful international cooperation experiences [20][23] - **Comparison between H - shares and A - shares**: H - shares have a larger scale, higher revenue, more listed Biotech companies, and lower valuations than A - shares. The proportion of innovative drugs in H - shares is also higher [36][39] 3.2 Industry Analysis - **Development Stages**: From 2015 - 2025, the innovative drug industry has gone through preliminary exploration (2015 - 2018), capital boom (2019 - 2021), deep adjustment (2022 - 2024), and recovery (2025) stages [2] - **Policy Support**: Policies have evolved from governance system innovation to continuous optimization and national - level support. Domestic policies have accelerated the approval process and improved the commercialization of innovative drugs through measures like optimizing the review and approval process and promoting医保access [2][60] - **Ecosystem Features**: The 18A channel in Hong Kong provides financing for unprofitable biotech companies. Overseas cooperation has led to the re - evaluation of innovative drug companies' valuations, with increasing cooperation between Chinese and international pharmaceutical giants [76][80] - **Internationalization Potential**: China has achieved breakthroughs in the quantity, quality, and technology of innovative drugs. The number of self - developed innovative drugs ranks first globally, the proportion of FIC molecules ranks second, and the gap in drug listing time between China and foreign countries has been significantly shortened [88][90][92] 3.3 ETF Product Introduction - **ETF General Information**: The GF China Securities Hong Kong Innovative Drug ETF was established on July 1, 2022, tracking the China Securities Hong Kong Innovative Drug Index. It has good liquidity, with a fund scale of 16.76 billion yuan as of August 6, 2025, and its daily trading volume has increased significantly [99] - **Features and Advantages**: It has high - purity industry focus and concentration, with the weight of bioproducts and chemical pharmaceuticals in the index reaching 92.5%, and the top ten component stocks' concentration reaching 70.59%. The industry is in a period of intensive realization, and policies provide full - chain support [105][106] - **Configuration Attributes**: It is an efficient tool for investors to allocate to the Hong Kong Biotech track, helping to avoid individual stock R & D risks. It also has medium - to - long - term rotation allocation value, with the index's one - year return ranking first among QDII stock funds and significant south - bound capital inflows [107][108]

Market Overview - US stock indices rebounded, influenced positively by Trump's market support, leading to a 0.68% rise in Hong Kong stocks [1] - San Francisco Fed President Daly indicated that the timing for interest rate cuts is approaching, with expectations for two 25 basis point cuts this year [1] - Goldman Sachs predicts three consecutive 25 basis point cuts starting in September, with a potential 50 basis point cut if unemployment rises further [1] Domestic Market Sentiment - A-share new account openings in July reached 1.96 million, a 71% year-on-year increase, indicating rising domestic confidence [2] - The stock of Upwind New Materials surged 20% after resuming trading, reigniting market enthusiasm [2] - The steel sector saw a significant rise, with Maanshan Iron & Steel's stock increasing over 15% due to improved loss forecasts and supportive policies [2] Industry Trends - The paper industry is experiencing a price increase, with major companies like Nine Dragons Paper and Lee & Man Paper announcing price hikes [2] - The eleventh batch of centralized drug procurement in China saw a record 45 companies applying for the same drug, intensifying competition in the generic drug market [3] - Investment is shifting towards innovative drugs, with companies like Junshi Biosciences seeing stock increases of nearly 34% due to promising clinical trials [3] Financial Support for Key Industries - A joint guideline from the central bank and seven departments aims to support financing for key manufacturing sectors, including integrated circuits and medical equipment [4] - AI-related companies like Longi Green Energy and Lenovo's server business are seeing stock increases due to new orders and market interest [4] Gaming Industry Performance - The domestic gaming market is projected to reach RMB 168 billion in sales by the first half of 2025, a 14.08% year-on-year increase [4] - Heartbeat Games anticipates a revenue increase of approximately 37% for the first half of 2025, driven by strong performance from self-developed games [4] Individual Company Highlights - Tencent's mobile game "Valorant: Source Action" is set to launch on August 19, with projected annual revenue exceeding RMB 6 billion [5] - Oriental Selection's stock surged nearly 17% ahead of its upcoming financial report, reflecting strong market performance [6] - The Macau gaming sector is experiencing a positive trend, with Morgan Stanley raising its revenue growth forecast for the year from 5% to 10% [6] Technological Advancements - Apple's breakthrough in brain-computer interface (BCI) technology allows users to control devices through thought, indicating a significant market opportunity [7] - The Chinese BCI market is expected to exceed RMB 3.8 billion by 2025, with a CAGR of approximately 20% [7] Investment Opportunities - Kelun-Bio has become a top holding in a major fund, indicating strong market confidence in its innovative drug pipeline [8] - The company has established multiple technology platforms and is expected to accelerate commercialization in 2025 [8]

Group 1 - In 2024, China approved 48 innovative drugs, more than five times the number in 2018, with nearly 40 approved in the first half of the year, indicating a significant "explosion effect" in the sector [1] - The number of innovative drugs approved by the U.S. FDA in 2024 is 50, only two more than China's total, suggesting that China may surpass developed countries in high-tech innovation in the pharmaceutical field [1] - The approval of innovative drugs in China is particularly focused on oncology, with lung cancer being a major health threat, leading to advancements in drug development that enhance treatment options and patient survival rates [1] Group 2 - Bispecific antibodies and antibody-drug conjugates are at the forefront of innovative oncology drugs, with only four bispecific drugs approved globally, one of which is China's innovative drug, Ivosidenib [2] - A head-to-head clinical trial published in The Lancet showed that Ivosidenib significantly outperformed the well-known cancer drug Pembrolizumab in terms of progression-free survival [2] - The first international phase III clinical study of Ivosidenib has concluded enrollment and is awaiting FDA review for lung cancer indications [2] Group 3 - The innovative drug Lurbinectedin was approved in March 2024, becoming the first antibody-drug conjugate for lung cancer indications globally, marking a shift from "catching up" to "leading" in drug development [3] - The rapid development of innovative drugs in China is attributed to supportive policies, including the recently approved "Implementation Plan for Supporting Innovative Drug Development" by the State Council [3] - Ivosidenib was approved in May 2024 and included in the medical insurance list the same year, allowing patients to benefit from insurance reimbursement starting January 1, 2025 [3] Group 4 - Among the 91 drugs newly included in the medical insurance directory in 2024, 33 were approved and included in the same year, reducing the time from approval to insurance coverage from about five years to one year [4] - The price of Ivosidenib dropped by 68% after being included in the insurance directory, significantly alleviating the financial burden on patients [4] - The five-year survival rate for cancer patients in China has improved from 33.3% a decade ago to 43.7% by the end of 2023, translating to an additional 500,000 lives saved each year [5] Group 5 - Despite rapid development, the Chinese innovative drug market faces challenges such as homogenization and lack of clear clinical advantages, leading to "involution" in competition [6] - The National Medical Insurance Administration emphasizes the need to support true innovation and differentiated innovation to guide the development of the biopharmaceutical industry [6] - New measures have been introduced to utilize medical insurance data for innovative drug research and development, enhancing the efficiency of innovation [7] Group 6 - A new commercial health insurance directory for innovative drugs has been established, allowing for the inclusion of high-value drugs that exceed basic insurance coverage [8] - The commercial health insurance sector in China is growing, with a premium income of 977.3 billion yuan in 2024, indicating a potential for increased support for innovative drugs [9] - The establishment of the commercial health insurance directory aims to alleviate the financial burden on patients while ensuring sustainable development for innovative drug companies [10] Group 7 - Companies can apply for inclusion in both the medical insurance directory and the commercial health insurance directory, with the latter allowing for greater involvement of insurance companies in the decision-making process [11]

Investment Rating - The report maintains an investment rating of "Leading the Market-B" for the biopharmaceutical industry, indicating an expected price increase exceeding the benchmark index by over 10% [10]. Core Insights - The PD-1(L1)/VEGF dual antibody is highlighted as a potential cornerstone drug for tumor immunotherapy, showing significant efficacy in various cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer [3][4]. - Multiple phase III clinical trials for PD-1(L1)/VEGF dual antibodies have achieved progression-free survival (PFS) endpoints, demonstrating clear benefits in first-line treatments for several tumor types [3][4]. - The report emphasizes the promising survival benefits of IBI363 in NSCLC, colorectal cancer, and melanoma, marking it as a breakthrough in clinical outcomes [3]. Summary by Sections Market Performance - The biopharmaceutical industry has shown strong market performance over the past year, with significant advancements in innovative drug development [1]. Drug Evaluation - The report discusses the efficacy of various drugs, including: - Ivoxi in first-line PD-L1 positive NSCLC achieving an overall response rate (ORR) of 50.0% and a disease control rate (DCR) of 89.9% [4]. - Ivoxi combined with chemotherapy in squamous NSCLC showing an ORR of 71.4% and a DCR of 90.5% [4]. - PM8002 demonstrating an ORR of 78.6% in first-line triple-negative breast cancer (TNBC) [6]. Clinical Trial Results - Ivoxi's combination therapies in various cancers have shown promising results: - In MSS colorectal cancer, the combination with FOLFOXIRI achieved an ORR of 81.8% [5]. - In head and neck squamous cell carcinoma, Ivoxi alone had an ORR of 30% [5]. - PM8002 in second-line small cell lung cancer (SCLC) showed a median overall survival (mOS) of 14.3 months [6]. Future Outlook - The report suggests that the ongoing clinical trials and the development of PD-1/VEGF dual antibodies could lead to significant advancements in cancer treatment, positioning the industry for continued growth [3][4].

Core Insights - The report highlights the strong performance of the U.S. job market, with June non-farm employment data showing an increase of 147,000 jobs and a decrease in the unemployment rate from 4.2% to 4.1% [4] - The report notes the significant growth of the jewelry brand Zhou Li Fu, which went public on the Hong Kong Stock Exchange, raising approximately HKD 1.292 billion [5][6] - The report discusses the rapid expansion of 361 Degrees, which opened 49 new stores, establishing itself as a new landmark in urban sports consumption [6][7] Market Trends - The U.S. economy is experiencing a mild cooling phase, with concerns about the job market being alleviated by strong employment data [4] - The textile and apparel sector saw a 1.36% increase, while the light industry manufacturing sector rose by 0.58% [6] - The gold and jewelry retail sector reported a year-on-year growth of 21.8% in May, indicating a robust demand for gold and jewelry products [7] Company Performance - Zhou Li Fu's revenue is projected to grow from CNY 3.102 billion in 2022 to CNY 5.718 billion in 2024, with a compound annual growth rate (CAGR) of 35.8% [5] - The net profit of Zhou Li Fu is expected to increase from CNY 575 million in 2022 to CNY 706 million in 2024, with a CAGR of 10.8% [5] - Tao Tao Vehicle's net profit for the first half of 2025 is projected to be between CNY 310 million and CNY 360 million, representing a year-on-year growth of 70.34% to 97.81% [14][16] Industry Developments - The global regulatory framework for stablecoins is advancing, with significant legislative actions in the U.S., EU, and Hong Kong [9][10] - The report emphasizes the entry of traditional financial institutions and tech giants into the stablecoin market, enhancing the ecosystem [9] - The report also highlights the potential for Real World Assets (RWA) to create new growth opportunities for stablecoins [10] Investment Recommendations - The report recommends focusing on companies with strong mid-year performance, particularly in the textile and apparel sector, such as Anta Sports and 361 Degrees [6][7] - In the gold and jewelry sector, companies like Lao Pu Gold and Chao Hong Ji are highlighted as having strong mid-year performance potential [7] - The report suggests monitoring the progress of virtual asset licensing in Hong Kong and the core application scenarios for stablecoins in the long term [12]

Core Insights - Lung cancer remains the leading cause of cancer-related deaths globally, with ongoing research and development of innovative drugs targeting this disease [1][2] - A total of 2813 drugs are currently in development for lung cancer indications, with a significant focus on non-small cell lung cancer (NSCLC) [2] - In the first half of this year, 9 innovative drugs for lung cancer have been approved, providing new treatment options for patients [3] Group 1: Drug Development Trends - The number of drugs in development for lung cancer has increased from 1655 in November 2022 to 2813 by July 2023, with the majority targeting NSCLC [2] - Among the 2813 drugs, small molecule drugs are the most prevalent, totaling 1028, followed by monoclonal antibodies (264), antibody-drug conjugates (ADC) (226), and bispecific antibodies (110) [2] - The most common drug targets include EGFR (66 drugs), PD-1 (42 drugs), and PD-L1 (27 drugs) [2] Group 2: Recent Drug Approvals - The 9 newly approved lung cancer drugs include products from major companies such as Johnson & Johnson, Bristol-Myers Squibb, and domestic firms like Hengrui Medicine and Hansoh Pharma [3][5] - Johnson & Johnson's Evotazumab is the first bispecific antibody approved for lung cancer, initially for second-line treatment of EGFR exon 20 insertion mutations [4] - The domestic drug Luconisumab, developed by Kelun-Biotech, is the second globally and the first in China ADC targeting TROP2, approved for treating advanced NSCLC [5] Group 3: Emerging Treatment Strategies - The approval of new drugs is addressing rare mutations such as EGFR exon 20 insertion, which accounts for 4%-10% of EGFR mutations and has poor prognosis with existing treatments [3] - The PD-1/VEGF bispecific antibody Ivosidenib has been approved for first-line treatment of PD-L1 positive NSCLC, marking a significant advancement in immunotherapy [7] - The introduction of drugs targeting KRAS mutations, previously considered "undruggable," indicates a shift in treatment possibilities for advanced NSCLC [6]

Group 1 - Core product Lukanasatuzumab (SAC-TMT) received breakthrough therapy designation from China's National Medical Products Administration (NMPA) for treating locally advanced or metastatic non-squamous non-small cell lung cancer without driver gene mutations [1] - This is the fifth breakthrough therapy designation for Lukanasatuzumab, which is an innovative antibody-drug conjugate (ADC) targeting advanced solid tumors such as non-small cell lung cancer, breast cancer, gastric cancer, and gynecological tumors [1][2] - Lukanasatuzumab has two approved indications in China, including treatment for unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) and EGFR mutation-positive non-small cell lung cancer after platinum-based chemotherapy [2] Group 2 - The company plans to place 5.918 million H-shares at a price of HKD 331.8 per share, raising approximately HKD 1.943 billion, marking the largest new share placement in the Hong Kong biopharmaceutical sector this year [3] - Proceeds from the placement will be used for product research and development, clinical trials, regulatory filings, manufacturing, and commercialization, aiming to enhance R&D capabilities and expand the product pipeline [3] - The company has seen a cumulative stock price increase of 110.04% this year, reflecting strong market interest in innovative drug concepts [3]

Market Overview - The Hang Seng Index is testing the March high of 24,874 points, supported by a basket of financial policies from mainland China aimed at stabilizing the market, including reserve requirement ratio cuts and interest rate reductions [2] - The market is optimistic about the new round of negotiations in June, although trade war news remains volatile, and the Hang Seng Index's valuation has returned to reasonable levels, requiring significant positive developments in trade agreements and corporate earnings to maintain upward momentum [2][5] Macro Focus - The World Bank has significantly lowered its GDP forecast for the US this year to 1.4%, while maintaining China's forecast at 4.5% [3][7] - The US and China have reportedly reached a framework agreement during trade talks in Geneva, with further negotiations expected [7] Corporate News - Meituan's CFO stated that share buybacks will continue to be an important way to return value to shareholders amid concerns over the company's stock price performance [4][9] - Meituan's CEO emphasized that the commercialization of new technologies is still constrained by airspace limitations and public acceptance [9] - JD.com is reportedly expanding into the hotel and travel industry, actively recruiting talent with experience from Meituan and other companies [9][10] Industry Insights - The pharmaceutical sector is seeing renewed collaboration between Chinese and American companies amid manageable geopolitical risks [6] - AI concept stocks are gaining attention with advancements in large model upgrades [6] - The energy sector is preparing for increased demand during the summer, while coal prices continue to decline [6] Investment Opportunities - The logistics technology sector is experiencing significant growth, with Cainiao reporting over 60% year-on-year growth in global customer numbers and expectations for overseas sales growth to surpass domestic sales [9] - The electric vehicle industry is witnessing major players like BYD and Geely standardizing payment terms with suppliers to enhance cash flow efficiency [10]